ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
low risk factor · long-only model fund

Foundry Healthcare StdTurn Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FSTHHYPOTHETICAL MODEL
Since ’99
−72%
Expense Ratio
0.45%
placeholder
Holdings
98
cap-weighted
Inception
Aug 2021
placeholder
Full Sharpe
-0.05
Ann. Return (LS)
-1.3%
Ann. Volatility
24.8%
Max Drawdown
-85.9%
Test Sharpe ’19–26
0.05
Test FF5 α (ann.)
-1.8%
vs Fama-French 5
Test FF5 α t-stat
-0.26
not significant
Monthly turnover
13%
of the long leg, per rebalance
Cumulative return (LS)
-72%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.59
what this fund holds
Long leg ann. return
8.6%
buyable, long-only
Long-short Sharpe
-0.05
requires shorting
Bottom bucket ann. return
9.9%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

98 of 98 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
23.59%
2JNJ
JOHNSON & JOHNSONHealthcare$609.12B
12.94%
3ABBV
ABBVIE INCHealthcare$449.63B
9.55%
4UNH
UNITEDHEALTH GROUP INCHealthcare$386.95B
8.22%
5MRK
MERCK & CO INCHealthcare$314.90B
6.69%
6TMO
THERMO FISHER SCIENTIFIC INCHealthcare$197.88B
4.20%
7AMGN
AMGEN INCHealthcare$197.69B
4.20%
8ABT
ABBOTT LABORATORIESHealthcare$175.37B
3.73%
9GILD
GILEAD SCIENCES INCHealthcare$166.72B
3.54%
10DHR
DANAHER CORPHealthcare$144.26B
3.06%
11CVS
CVS HEALTH CORPHealthcare$137.12B
2.91%
12VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
2.62%
13SYK
STRYKER CORPHealthcare$122.63B
2.60%
14MCK
MCKESSON CORPHealthcare$101.14B
2.15%
15HCA
HCA HEALTHCARE INCHealthcare$82.34B
1.75%
16COR
CENCORA INCHealthcare$59.91B
1.27%
17ONC
BEONE MEDICINES LTDHealthcare$34.68B
0.74%
18ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
0.53%
19INCY
INCYTE CORPHealthcare$23.42B
0.50%
20DGX
QUEST DIAGNOSTICS INCHealthcare$23.32B
0.50%
21STE
STERIS PLCHealthcare$21.26B
0.45%
22MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
0.33%
23EXEL
EXELIXIS INCHealthcare$14.06B
0.30%
24SMMT
SUMMIT THERAPEUTICS INCHealthcare$10.72B
0.23%
25ENSG
ENSIGN GROUP INCHealthcare$10.01B
0.21%
26KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
0.20%
27HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.20%
28IONS
IONIS PHARMACEUTICALS INCHealthcare$8.99B
0.19%
29SYRE
SPYRE THERAPEUTICS INCHealthcare$8.70B
0.18%
30IMVT
IMMUNOVANT INCHealthcare$8.27B
0.18%
31BLLN
BILLIONTOONE INCHealthcare$5.99B
0.13%
32BLCO
BAUSCH & LOMB CORPHealthcare$5.80B
0.12%
33AMRX
AMNEAL PHARMACEUTICALS INCHealthcare$5.69B
0.12%
34RDNT
RADNET INCHealthcare$4.89B
0.10%
35ACAD
ACADIA PHARMACEUTICALS INCHealthcare$4.38B
0.09%
36EWTX
EDGEWISE THERAPEUTICS INCHealthcare$4.28B
0.09%
37CON
CONCENTRA GROUP HOLDINGS PARENT INCHealthcare$4.04B
0.09%
38ICUI
ICU MEDICAL INCHealthcare$3.94B
0.08%
39DNLI
DENALI THERAPEUTICS INCHealthcare$3.70B
0.08%
40NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
0.08%
41GPCR
STRUCTURE THERAPEUTICS INCHealthcare$3.45B
0.07%
42PRVA
PRIVIA HEALTH GROUP INCHealthcare$3.39B
0.07%
43IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.07%
44IRON
DISC MEDICINE INCHealthcare$2.91B
0.06%
45SUPN
SUPERNUS PHARMACEUTICALS INCHealthcare$2.79B
0.06%
46GRDN
GUARDIAN PHARMACY SERVICES INCHealthcare$2.57B
0.05%
47PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
0.05%
48MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.05%
49AVAH
AVEANNA HEALTHCARE HOLDINGS INCHealthcare$2.11B
0.04%
50SGRY
SURGERY PARTNERS INCHealthcare$2.09B
0.04%
51PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.04%
52MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.04%
53ZYME
ZYMEWORKS INCHealthcare$1.77B
0.04%
54INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
0.03%
55SEPN
SEPTERNA INCHealthcare$1.51B
0.03%
56AHCO
ADAPTHEALTH CORPHealthcare$1.49B
0.03%
57PNTG
PENNANT GROUP INCHealthcare$1.46B
0.03%
58ARDT
ARDENT HEALTH INCHealthcare$1.46B
0.03%
59KMTS
KESTRA MEDICAL TECHNOLOGIES LTDHealthcare$1.43B
0.03%
60PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.03%
61USPH
U S PHYSICAL THERAPY INCHealthcare$1.12B
0.02%
62LMRI
LUMEXA IMAGING HOLDINGS INCHealthcare$1.07B
0.02%
63BVS
BIOVENTUS INCHealthcare$1.01B
0.02%
64LBRX
LB PHARMACEUTICALS INCHealthcare$901M
0.02%
65HSTM
HEALTHSTREAM INCHealthcare$832M
0.02%
66AURA
AURA BIOSCIENCES INCHealthcare$723M
0.02%
67BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS INCHealthcare$686M
0.01%
68SGP
SPYGLASS PHARMA INCHealthcare$661M
0.01%
69GYRE
GYRE THERAPEUTICS INCHealthcare$587M
0.01%
70ANGO
ANGIODYNAMICS INCHealthcare$558M
0.01%
71NPCE
NEUROPACE INCHealthcare$548M
0.01%
72EIKN
EIKON THERAPEUTICS INCHealthcare$529M
0.01%
73KIDS
ORTHOPEDIATRICS CORPHealthcare$494M
0.01%
74NRC
NRC HEALTHHealthcare$491M
0.01%
75OFIX
ORTHOFIX MEDICAL INCHealthcare$468M
0.01%
76VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.01%
77SI
SHOULDER INNOVATIONS INCHealthcare$448M
0.01%
78BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.01%
79DMAC
DIAMEDICA THERAPEUTICS INCHealthcare$393M
0.01%
80FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
0.01%
81CV
CAPSOVISION INCHealthcare$335M
0.01%
82CARL
CARLSMED INCHealthcare$317M
0.01%
83FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.01%
84MASS
908 DEVICES INCHealthcare$278M
0.01%
85SGHT
SIGHT SCIENCES INCHealthcare$274M
0.01%
86TTRX
TURN THERAPEUTICS INCHealthcare$272M
0.01%
87TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.01%
88SMTI
SANARA MEDTECH INCHealthcare$229M
0.00%
89UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.00%
90FOCL
FOCAL INCHealthcare$204M
0.00%
91ACOG
ALPHA COGNITION INCHealthcare$185M
0.00%
92INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.00%
93OWLT
OWLET INCHealthcare$162M
0.00%
94RCEL
AVITA MEDICAL INCHealthcare$157M
0.00%
95JYNT
JOINT CORPHealthcare$127M
0.00%
96ICCC
IMMUCELL CORPHealthcare$101M
0.00%
97CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.00%
98EXOZ
EXOZYMES INCHealthcare$51M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $4.71T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

98 classified
Value
Blend
Growth
Large
Mid
Small
8%5
49%19
41%13
<1%6
<1%7
<1%7
<1%13
<1%7
<1%12

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 67% toward Growth. Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt99% → Large
SmallLarge
Value ↔ growth tilt67% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 98 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    64.0%
    Margin
    -11.0%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 98 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.1 (95% CI 0.7-1.2)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
10.4%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.08x
within
parametric
0.92x
within
cornish fisher
0.86x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 18%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2001
Before publication (pre-2001)
-0.16
Sharpe · -8.6% p.a.
January 1999December 2001 · 36 mo
Since publication
-0.02
Sharpe · -0.4% p.a.
January 2002July 2026 · 295 mo
Change in Sharpe+0.14Sharpe strengthened since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
46%
12 of 26 3-year windows made money
Worst window
-1.04
Sharpe, January 2009 – December 2011
January 1999July 2026
Median Sharpe
-0.02
Dispersion
0.43
Best window
0.50

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.25.8%-21.0%
3 yearsp.a.12.7%-1.7%
5 yearsp.a.8.6%9.2%
10 yearsp.a.11.8%-2.0%
Since inceptionp.a.7.8%-4.5%
Calendar years
YearLong legLong-short
20267 mo3.5%-12.3%
202525.4%5.2%
20247.1%12.7%
20234.9%-16.0%
2022-3.6%32.7%
202126.0%21.2%
202016.5%-27.3%
201920.5%-12.7%
201810.0%9.0%
201719.6%-10.1%
20164.1%31.7%
20153.5%-5.5%
201423.2%-11.7%
201342.1%-11.4%
201213.7%-10.7%
201113.2%5.3%
20102.5%-12.1%
200912.1%-27.3%
2008-20.4%9.4%
20076.8%-0.8%
20067.3%7.7%
20055.3%5.6%
2004-2.9%-14.1%
200312.2%-18.9%
2002-19.4%32.0%
2001-12.4%-6.7%
200037.0%-35.4%
1999-13.4%-19.1%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FSTH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-08-19 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$4.71T

Methodology

The Foundry Healthcare StdTurn Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a StdTurn signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.